Aytu Biopharma (AYTU) Cash from Investing Activities (2015 - 2025)
Aytu Biopharma's (AYTU) quarterly Cash from Investing Activities came in at -$17000.0 in Q4 2025, down 111.72% year-on-year from $145000.0 in Q4 2024, and up 99.44% on a QoQ basis from -$3.0 million in Q2 2025.
Aytu Biopharma (AYTU) Cash from Investing Activities (2015 - 2025) Analysis & Trends
Aytu Biopharma (AYTU) has 11 years of Cash from Investing Activities data on file, last reported at -$17000.0 in Q4 2025.
- On a quarterly basis, Cash from Investing Activities fell 111.72% year-over-year to -$17000.0 in Q4 2025; TTM through Mar 2026 was -$3.0 million, a 817.26% decrease from a year earlier, with the FY2025 full-year figure at -$2.6 million, down 678.12% from the prior year.
- Cash from Investing Activities for Q4 2025 stood at -$17000.0, up from -$3.0 million in the prior quarter.
- Over the last five years, Cash from Investing Activities for AYTU reached as high as $381000.0 in Q3 2024 and fell as low as -$3.1 million in Q4 2021.
- Historically, Cash from Investing Activities has averaged -$483166.7 across 5 years, with a median of -$57000.0 in 2024.
- Across the five-year window, Cash from Investing Activities sank 10070.0% in 2021 and soared 601.32% in 2024, its largest moves.
- Year by year, Cash from Investing Activities stood at -$3.1 million in 2021, then jumped by 99.84% to -$5000.0 in 2022, then tumbled by 3380.0% to -$174000.0 in 2023, then soared by 183.33% to $145000.0 in 2024, then tumbled by 111.72% to -$17000.0 in 2025.
- Per Business Quant data, the three most recent Cash from Investing Activities figures were -$17000.0 in Q4 2025, -$3.0 million in Q2 2025, and -$69000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 229.00 Mn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | -87.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -369.95 Mn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 743.70 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 277.40 Mn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | -506.20 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -60.00 Mn |
| 10 | Aytu Biopharma | 21.45 Mn | -5.27 Mn | 7.60 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -17,000.00 |
| Dec 31, 2025 | -17,000.00 |
| Jun 30, 2025 | -3.02 Mn |
| Jun 30, 2025 | -3.02 Mn |
| Mar 31, 2025 | -69,000.00 |
| Mar 31, 2025 | -69,000.00 |
| Dec 31, 2024 | 145,000.00 |
| Dec 31, 2024 | 145,000.00 |
| Sep 30, 2024 | 381,000.00 |
| Sep 30, 2024 | 381,000.00 |
| Jun 30, 2024 | -34,000.00 |
| Jun 30, 2024 | -34,000.00 |
| Mar 31, 2024 | -45,000.00 |
| Mar 31, 2024 | -45,000.00 |
| Dec 31, 2023 | -174,000.00 |
| Dec 31, 2023 | -174,000.00 |
| Sep 30, 2023 | -76,000.00 |
| Sep 30, 2023 | -76,000.00 |
| Jun 30, 2023 | -155,000.00 |
| Jun 30, 2023 | -155,000.00 |